Literature DB >> 12925214

Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.

Rochelle L Mandelcorn-Monson1, Neil H Shear, Eddy Yau, Suryaprakash Sambhara, Brian H Barber, David Spaner, Mark A DeBenedette.   

Abstract

Vitiligo is a common depigmentation disorder thought to result from autoimmune destruction of melanocytes. Recent studies suggest a role for cell-mediated immune responses to melanocyte differentiation antigens, including gp100, MelanA/MART-1, and tyrosinase, in vitiligo pathogenesis. This study investigated T cell reactivity to MelanA/MART-1, tyrosinase, and gp100, in HLA-A2-positive patients with vitiligo. Melanocyte-specific T cell responses were measured ex vivo via enzyme-linked immunospot assay following stimulation with MelanA/MART-1, tyrosinase, and modified gp100 epitopes. Antigen-specific T lymphocyte reactivity to gp100 peptides was seen in 15 of 17 (88%) patients, with many demonstrating very high reactivity at levels comparable with those observed with common recall antigens. Reactivity to gp100 was noted to be associated with disease activity. Antigen-specific T lymphocyte reactivity to MelanA/MART-1 and tyrosinase peptides was not observed ex vivo in our patients, and only one patient demonstrated responses to MelanA/MART-1 and tyrosinase peptides following in vitro re-stimulation. Our findings implicate T cell reactivity to gp100 in patients with active disease and support the concept of an immunopathologic mechanism in vitiligo, in which cell-mediated responses to normal melanocyte antigens play a crucial part.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925214     DOI: 10.1046/j.1523-1747.2003.12413.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  30 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

Review 3.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 4.  Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments.

Authors:  Torello Lotti; Matteo Zanardelli; Angelo Massimiliano D'Erme
Journal:  Wien Med Wochenschr       Date:  2014-07-25

Review 5.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

6.  GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.

Authors:  Matthew P Rausch; Kari R Irvine; Paul A Antony; Nicholas P Restifo; Peter Cresswell; K Taraszka Hastings
Journal:  J Immunol       Date:  2010-07-28       Impact factor: 5.422

Review 7.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.

Authors:  S You; Y-H Cho; J-S Byun; E-C Shin
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

9.  Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo.

Authors:  Mitesh Dwivedi; Naresh C Laddha; Kriti Shah; Bela J Shah; Rasheedunnisa Begum
Journal:  J Interferon Cytokine Res       Date:  2013-06-18       Impact factor: 2.607

Review 10.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.